SHR-7367
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
December 21, 2025
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=100 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
November 18, 2025
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=100 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1/2 trial • Oncology • Solid Tumor
August 06, 2025
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=22 | Active, not recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | N=182 ➔ 22
Enrollment change • Enrollment closed • Solid Tumor
May 12, 2023
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=182 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Oncology • Solid Tumor
February 22, 2023
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=182 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1